Supplementary Table 1. Clinical characteristics of patients without sufficient observations of lipid and glucose parameters from two to eight months after PCI.
| Variables |
Patients enrolled in the main analysis (n = 831) |
Patients excluded due to insufficient measurements (n = 679) |
p value |
|---|---|---|---|
| Age, years | 69.4±11.2 | 71.8±12.0 | ＜0.001 |
| Women, n (%) | 172 (20.7) | 162 (23.9) | 0.14 |
| BMI, kg/m2 | 23.8±3.8 | 23.6±3.9 | 0.26 |
| History of diabetes mellitus, n (%) | 431 (51.9) | 318 (46.8) | 0.05 |
| History of dyslipidemia, n (%) | 720 (86.6) | 522 (76.9) | ＜0.001 |
| History of hypertension, n (%) | 679 (81.7) | 511 (75.3) | ＜0.01 |
| History of COPD, n (%) | 51 (6.1) | 54 (8.0) | 0.17 |
| Uses of antihypertensive drugs, n (%) | 565 (68.0) | 470 (69.2) | 0.61 |
| CCB, n (%) | 247 (29.7) | 240 (35.3) | ＜0.05 |
| ACEi, n (%) | 221 (26.6) | 123 (18.1) | ＜0.001 |
| ARB, n (%) | 226 (27.2) | 190 (28.0) | 0.73 |
| Thiazides, n (%) | 26 (3.1) | 15 (2.2) | 0.27 |
| Alpha-blockers, n (%) | 15 (1.8) | 15 (2.2) | 0.58 |
| Beta-blockers, n (%) | 371 (44.6) | 279 (41.1) | 0.17 |
| MRB, n (%) | 74 (8.9) | 54 (8.0) | 0.51 |
| eGFR, mL/min/1.73 m2 | 60.5±20.8 | 56.3±24.1 | ＜0.001 |
| LDL-C, mg/dl | 106.6±38.2 | 102.3±38.7 | ＜0.05 |
| HDL-C, mg/dl | 46.7±12.2 | 48.0±14.0 | 0.06 |
| TG, mg/dl | 124.0 (86.5, 186.0) | 120.0 (80.0, 176.0) | 0.06 |
| Hemoglobin A1c, % | 6.1 (5.7, 7.0) | 5.9 (5.6, 6.6) | ＜0.001 |
| Uric acid, mg/dl | 5.9±1.5 | 5.9±1.7 | 0.53 |
| hsCRP, mg/dl | 0.2 (0.1, 0.6) | 0.2 (0.1, 0.6) | 0.40 |
| Uses of lipid-lowering drugs, n (%) | 620 (74.6) | 488 (71.9) | 0.23 |
| Statins, n (%) | 616 (74.1) | 476 (70.1) | 0.08 |
| Fibrates, n (%) | 11 (1.3) | 13 (1.9) | 0.36 |
| Ezetimibe, n (%) | 65 (7.8) | 54 (8.0) | 0.93 |
| PCSK9 inhibitors, n (%) | 1 (0.1) | 1 (0.1) | 0.89 |
| Uses of antidiabetic drugs | 209 (25.2) | 149 (21.9) | 0.15 |
| Insulin, n (%) | 61 (7.3) | 39 (5.7) | 0.21 |
| SGLT2 inhibitors, n (%) | 55 (6.6) | 34 (5.0) | 0.19 |
| Biguanides, n (%) | 21 (2.5) | 18 (2.7) | 0.88 |
Data are expressed as mean±SD for unskewed variables, median (interquartile) for skewed variables, and numbers (%) for categorical variables. The cases excluded excluded due to the insufficient measurements had higher age and lower rates in diabetes mellitus, dyslipidemia, and hypertension compared to the cases enrolled in the primary analysis. ACEi = angiotensin-converting-enzyme inhibitors, ARB = angiotensin receptor blockers, BMI = body mass index, CCB = calcium channel blockers, COPD = chronic obstructive pulmonary disease, hsCRP = high-sensitive C-reactive protein, eGFR = estimated glomerular filtration rate, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, MRB = mineralocorticoid receptor blockers, PCSK9 = proprotein convertase subtilisin/kexin type 9; SD = standard deviation, SGLT2 = sodium-glucose co-transporter 2, TG = triglyceride.